Aspira Pathlab & Diagnostics
Healthcare Services
540788 BSE
₹140.35
Close ·
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹140.35 +80.35 +134% 1Y
Start ₹60.00
Key Fundamentals
MicrocapHealthcare ServicesHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- 2.84%
- Debt to Equity
- 1.13
- EPS (TTM)
- −₹0.44
- Book Value
- ₹7.09
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 19.80
- ROE
- 0.69%
- Dividend Yield
- 0.00%
- EBITDA
- ₹3.90 Cr
- 52W High
- ₹149.99
- 52W Low
- ₹49.00
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
57 Good
Data confidence 91/100
Category scores
- Quality
- 64
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 35
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 59
- Good
- Sales & profit trajectory 9% weight
- Financial Health
- 46
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 99
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Debtor days have improved from 42.1 to 25.3 days.
- Promoter holding has increased by 28.2% over last quarter.
Weaknesses
5- Stock is trading at 16.0 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.59% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.0.53 Cr.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 4 | 12 |
| Oscillators | Bearish | 3 | 4 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Bearish
3
Neutral
4
Bullish
2
Overall
Strong Bullish
Bearish
3
Neutral
4
Bullish
12
Moving Averages
Strong Bullish
Bearish
0
Neutral
0
Bullish
10
Key readings
- RSI (14)
- 66.85
- Neutral
- MACD (12,26,9)
- 5.32
- Bullish
- SMA (50)
- 114.05
- Bullish
- SMA (200)
- 91.96
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | Zero base |
|---|---|
| 5Y | +10.43% |
| 3Y | +19.99% |
| 1Y | +13.55% |
| TTM | +14.50% |
Net profit
| 10Y | +5.24% |
|---|---|
| 5Y | −48.50% |
| 3Y | Turned to profit |
| 1Y | −97.58% |
| TTM | Turned to loss |
Operating cash flow
| 10Y | Turned positive |
|---|---|
| 5Y | −23.87% |
| 3Y | Turned positive |
| 1Y | −22.87% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | No sales |
|---|---|
| 5Y | −17.30 pp |
| 3Y | −5.23 pp |
| 1Y | −10.34 pp |
| TTM | −13.73 pp |
Revenue by year
| Mar 2017 | ₹0.76 Cr |
|---|---|
| Mar 2018 | ₹4.36 Cr |
| Mar 2019 | ₹7.64 Cr |
| Mar 2020 | ₹8.42 Cr |
| Mar 2021 | ₹15.21 Cr |
| Mar 2022 | ₹19.54 Cr |
| Mar 2023 | ₹14.46 Cr |
| Mar 2024 | ₹13.20 Cr |
| Mar 2025 | ₹22.00 Cr |
| Mar 2026 | ₹24.98 Cr |
Net profit by year
| Mar 2017 | −₹2.72 Cr |
|---|---|
| Mar 2018 | −₹5.58 Cr |
| Mar 2019 | −₹5.18 Cr |
| Mar 2020 | −₹4.24 Cr |
| Mar 2021 | ₹1.38 Cr |
| Mar 2022 | ₹4.46 Cr |
| Mar 2023 | −₹0.09 Cr |
| Mar 2024 | −₹2.67 Cr |
| Mar 2025 | ₹2.07 Cr |
| Mar 2026 | ₹0.05 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.6 | 3.32 | 3.46 | 3.82 | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 | 8.09 | 5.12 | 6.52 | 6.17 |
| Expenses | 2.92 | 3.68 | 3.83 | 3.95 | 4.29 | 4.83 | 4.65 | 4.73 | 4.44 | 5.9 | 6.33 | 6.85 | 5.83 |
| Operating Profit | −0.32 | −0.36 | −0.37 | −0.13 | 0.35 | 1.35 | 0.76 | 1.05 | 0.81 | 2.19 | −1.21 | −0.33 | 0.34 |
| OPM % | −12.31% | −10.84% | −10.69% | −3.4% | 7.54% | 21.84% | 14.05% | 18.17% | 15.43% | 27.07% | −23.63% | −5.06% | 5.51% |
| Other Income | 0.1 | 0.14 | 0.1 | 0.08 | 0.09 | 0.08 | 0.09 | 0.13 | 0.11 | 0.14 | 0.13 | 0.14 | 0.12 |
| Interest | 0.1 | 0.1 | 0.09 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.1 | 0.1 | 0.1 | 0.09 |
| Depreciation | 0.39 | 0.39 | 0.38 | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 | 0.4 | 0.38 | 0.4 | 0.41 |
| PBT | −0.71 | −0.71 | −0.74 | −0.51 | −0.02 | 0.99 | 0.37 | 0.72 | 0.46 | 1.83 | −1.56 | −0.69 | −0.04 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −0.72 | −0.71 | −0.74 | −0.5 | −0.02 | 0.99 | 0.38 | 0.72 | 0.47 | 1.84 | −1.56 | −0.69 | −0.04 |
| EPS (₹) | −0.7 | −0.69 | −0.72 | −0.49 | −0.02 | 0.96 | 0.37 | 0.7 | 0.46 | 1.79 | −1.52 | −0.67 | −0.04 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0.76 | 4.36 | 7.64 | 8.42 | 15.21 | 19.54 | 14.46 | 13.2 | 22 | 24.98 | 25.9 |
| Expenses | 0.14 | 0.23 | 3.34 | 8.24 | 10.88 | 10.25 | 11.69 | 13.16 | 12.86 | 14.38 | 18.44 | 23.52 | 24.91 |
| Operating Profit | −0.14 | −0.23 | −2.58 | −3.88 | −3.24 | −1.83 | 3.52 | 6.38 | 1.6 | −1.18 | 3.56 | 1.46 | 0.99 |
| OPM % | — | — | −339.47% | −88.99% | −42.41% | −21.73% | 23.14% | 32.65% | 11.07% | −8.94% | 16.18% | 5.84% | 3.82% |
| Other Income | 0.21 | 0.32 | 0.31 | 0.22 | 0.25 | 0.29 | 0.2 | 0.09 | 0.32 | 0.42 | 0.36 | 0.52 | 0.53 |
| Interest | 0 | 0.05 | 0.26 | 0.8 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | 0.35 | 0.39 | 0.39 |
| Depreciation | 0 | 0 | 0.2 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.49 | 1.54 | 1.59 |
| PBT | 0.07 | 0.04 | −2.73 | −5.58 | −5.18 | −4.21 | 1.39 | 4.46 | −0.09 | −2.67 | 2.08 | 0.05 | −0.46 |
| Tax % | 57.14% | 25% | 0% | 0% | 0% | 0.71% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | 0.02 | 0.03 | −2.72 | −5.58 | −5.18 | −4.24 | 1.38 | 4.46 | −0.09 | −2.67 | 2.07 | 0.05 | −0.45 |
| EPS (₹) | 0.09 | 0.13 | −5.24 | −10.75 | −6.32 | −4.56 | 1.34 | 4.33 | −0.09 | −2.59 | 2.01 | 0.05 | −0.44 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.25 | 2.25 | 5.19 | 5.19 | 8.19 | 9.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 |
| Reserves | 1.36 | 1.39 | 0.72 | −4.86 | −7.93 | −10.42 | −6.91 | −2.43 | −2.47 | −5.08 | −3.01 | −2.99 |
| Borrowings | 0 | 2.62 | 7.29 | 11.36 | 12.52 | 13.8 | 7.01 | 8.85 | 8.24 | 7.71 | 8.13 | 8.25 |
| Other Liabilities | 0.21 | 0.03 | 1.66 | 0.84 | 2.02 | 1.67 | 1.39 | 1.42 | 1.28 | 1.79 | 2.11 | 2.95 |
| Total Liabilities | 3.82 | 6.29 | 14.86 | 12.53 | 14.8 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 18.5 |
| Fixed Assets | 0 | 0.04 | 7.79 | 7.91 | 8.9 | 8.7 | 7.75 | 9.57 | 8.01 | 6.79 | 6.53 | 7.2 |
| CWIP | 0 | 0 | 0.25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.13 | 0 |
| Other Assets | 3.82 | 6.25 | 6.82 | 4.62 | 5.9 | 5.64 | 4.03 | 8.56 | 9.33 | 7.92 | 10.86 | 11.3 |
| Total Assets | 3.82 | 6.29 | 14.86 | 12.53 | 14.8 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 18.5 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | −0.37 | −1.29 | −4.81 | −3.39 | −1.87 | 5.67 | 2.03 | −0.01 | 1.05 | 1.88 | 1.45 |
| Investing | — | −0.02 | −10.14 | −0.77 | −1.97 | 0.24 | −0.09 | −0.51 | 0.16 | 0.14 | 0.07 | −0.8 |
| Financing | — | 2.64 | 8.91 | 6.52 | 3.35 | 1.27 | −2.17 | −1.35 | −0.94 | −0.95 | −0.99 | −1.14 |
| Net Cash Flow | — | 2.25 | −2.52 | 0.94 | −2 | −0.35 | 3.41 | 0.17 | −0.79 | 0.24 | 0.95 | −0.49 |
| Free Cash Flow | — | −0.41 | −8.41 | −5.81 | −3.9 | −1.92 | 5.37 | 1.42 | −0.15 | 0.79 | 1.71 | 0.75 |
| CFO/OP | — | 139 | 50 | 124 | 105 | 101 | 161 | 32 | −1 | −89 | 53 | 99 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | 43.22 | 29.3 | 38.22 | 26.01 | 40.8 | 83.87 | 59.07 | 61.94 | 38.99 | 25.28 |
| Inventory Days | — | — | 313 | 104 | 45.22 | 51.36 | 51.35 | 46.5 | 58.4 | 62.69 | 50.31 | 56.53 |
| Days Payable | — | — | 730 | 64.58 | 46.84 | 73.37 | 91.6 | 70.91 | 51.1 | 102 | 73 | 92.06 |
| Cash Conversion Cycle | — | — | −374 | 68.61 | 36.6 | 4 | 0.55 | 59.46 | 66.37 | 22.93 | 16.3 | −10.25 |
| Working Capital Days | — | — | −2,200 | −5.86 | −96.03 | −127 | 16.32 | 69.3 | 48.72 | 25.16 | 14.1 | −2.92 |
| ROCE % | — | 1.82% | −25.39% | −38.41% | −34.49% | −25.15% | 19.77% | 35.65% | 2.01% | −15.87% | 17.37% | 2.84% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aspira Pathlab & Diagnostics insights
58 extracted metrics across FY11–FY27.
Documents
- 23 May 2026
- General announcements 8 Oct 2026
Frequently Asked Questions about Aspira Pathlab & Diagnostics
What does Aspira Pathlab & Diagnostics Ltd do?
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services
Where is Aspira Pathlab & Diagnostics Ltd (ASPIRA) listed?
Aspira Pathlab & Diagnostics Ltd trades under code 540788 on the BSE.
Which sector does Aspira Pathlab & Diagnostics Ltd belong to?
Aspira Pathlab & Diagnostics Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the 52-week high and low of Aspira Pathlab & Diagnostics Ltd?
Over the last 52 weeks Aspira Pathlab & Diagnostics Ltd has traded between ₹49 and ₹149.99 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd reported a return on equity of 0.69%. Its debt-to-equity ratio is 1.13.
Company Information
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services
Website aspiradiagnostics.com
CEO Dr. Pankaj Jashwant Shah
Employees 141
Listed 28 Feb 2018
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540788.md for Aspira Pathlab & Diagnostics Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.